Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) Enterprise Value (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Enterprise Value for 16 consecutive years, with -$2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value fell 197.55% to -$2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.3 million, a 197.55% decrease, with the full-year FY2024 number at -$430000.0, up 85.29% from a year prior.
  • Enterprise Value was -$2.3 million for Q3 2025 at NovaBay Pharmaceuticals, up from -$5.3 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$430000.0 in Q4 2024 to a low of -$10.5 million in Q1 2021.
  • A 5-year average of -$4.8 million and a median of -$3.9 million in 2022 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: surged 85.29% in 2024, then plummeted 611.58% in 2025.
  • NovaBay Pharmaceuticals' Enterprise Value stood at -$7.5 million in 2021, then increased by 28.54% to -$5.4 million in 2022, then skyrocketed by 45.47% to -$2.9 million in 2023, then soared by 85.29% to -$430000.0 in 2024, then tumbled by 436.98% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Enterprise Value are -$2.3 million (Q3 2025), -$5.3 million (Q2 2025), and -$8.5 million (Q1 2025).